Andere Sprachen Vaxcyte, Inc.

Aktien

A2P6R6

US92243G1085

PCVX

Realtime-Estimate Cboe BZX Andere Börsenplätze 16:41:58 30.04.2024			% 5 Tage	% 1. Jan.
60,06 ^USD	-1,60 %		-0,46 %	-3,50 %

25.04.	Vaxcyte Insider verkaufte Aktien im Wert von $928,845, laut einer aktuellen SEC Einreichung	MT
22.04.	Vaxcyte-Insider verkauft Aktien im Wert von $490.199, laut einer aktuellen SEC-Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	25.04.
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	22.04.
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	02.04.
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31.03.
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31.03.
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.	31.03.
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing	21.03.
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants	04.03.
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants	04.03.
Vaxcyte Q4 Loss Widens	27.02.
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27.02.
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	15.02.
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03.02.
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	03.02.
Vaxcyte Insider Sold Shares Worth $357,500, According to a Recent SEC Filing	02.02.
Vaxcyte to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	01.02.
Vaxcyte Insider Sold Shares Worth $1,980,900, According to a Recent SEC Filing	31.01.
Vaxcyte Insider Sold Shares Worth $270,000, According to a Recent SEC Filing	31.01.
Vaxcyte Prices $750 Million Public Offering at $64 Per Share	31.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Vaxcyte, Inc.

Aktien

A2P6R6

US92243G1085

PCVX

Andere Sprachen

Filter